HYUNDAI FEED Inc (016790) - Cash Flow Conversion Efficiency
Based on the latest financial reports, HYUNDAI FEED Inc (016790) has a cash flow conversion efficiency ratio of 0.014x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.18 Billion ≈ $800.46K USD) by net assets (₩83.53 Billion ≈ $56.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is HYUNDAI FEED Inc's balance sheet to measure how much of total assets are equity-financed.
HYUNDAI FEED Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how HYUNDAI FEED Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 016790 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
HYUNDAI FEED Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of HYUNDAI FEED Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FACT II Acquisition Corp. Class A Ordinary Shares
NASDAQ:FACT
|
-0.001x |
|
Dong Hai JSC of Bentre
VN:DHC
|
0.005x |
|
DMS Co.Ltd
KQ:068790
|
0.056x |
|
Energy World Corporation Ltd
AU:EWC
|
-0.017x |
|
John Hancock Income Securities Closed Fund
NYSE:JHS
|
0.031x |
|
Land General Bhd
KLSE:3174
|
0.065x |
|
Cannara Biotech Inc
V:LOVE
|
0.072x |
|
ENIGMATIG LIMITED
NYSE MKT:EGG
|
0.008x |
Annual Cash Flow Conversion Efficiency for HYUNDAI FEED Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of HYUNDAI FEED Inc from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 016790 company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩88.93 Billion ≈ $60.27 Million |
₩860.48 Million ≈ $583.13K |
0.010x | -91.16% |
| 2023-12-31 | ₩-72.23 Billion ≈ $-48.95 Million |
₩-7.91 Billion ≈ $-5.36 Million |
0.110x | +282.63% |
| 2022-12-31 | ₩42.37 Billion ≈ $28.71 Million |
₩-2.54 Billion ≈ $-1.72 Million |
-0.060x | -165.51% |
| 2021-12-31 | ₩57.63 Billion ≈ $39.05 Million |
₩5.27 Billion ≈ $3.57 Million |
0.092x | -59.14% |
| 2020-12-31 | ₩58.97 Billion ≈ $39.96 Million |
₩13.21 Billion ≈ $8.95 Million |
0.224x | +343.11% |
| 2019-12-31 | ₩59.46 Billion ≈ $40.29 Million |
₩-5.48 Billion ≈ $-3.71 Million |
-0.092x | +66.92% |
| 2018-12-31 | ₩56.83 Billion ≈ $38.51 Million |
₩-15.83 Billion ≈ $-10.73 Million |
-0.279x | -262.98% |
| 2017-12-31 | ₩48.74 Billion ≈ $33.03 Million |
₩8.33 Billion ≈ $5.65 Million |
0.171x | -13.94% |
| 2016-12-31 | ₩44.51 Billion ≈ $30.16 Million |
₩8.84 Billion ≈ $5.99 Million |
0.199x | +876.19% |
| 2015-12-31 | ₩42.37 Billion ≈ $28.71 Million |
₩-1.08 Billion ≈ $-734.66K |
-0.026x | -- |
About HYUNDAI FEED Inc
HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more